Journal of Cerebral Blood Flow & Metabolism · 2019 · 20 citations · 24 references
MedicineNeurosciencePharmacologyMolecular ImagingMolecular NeuroscienceNeurochemistryLigand BindingNeurodegenerative Disease ImagingNeuroinflammationRadiopharmaceutical DesignRadiotracer DevelopmentTargeted RadiopharmaceuticalsFluorine-18 RadiopharmaceuticalsNeuroinflammation In Alzheimer DiseaseNon-specific Binding ReductionRadioligand Binding AssaysRadioligand ImagingRadiotracer SynthesisRadiotracers Targeting Translocator ProteinReceptor Targeted Radiotracers
[ 18 F]F-DPA, a novel translocator protein 18 kDa (TSPO)-specific radioligand for imaging neuroinflammation, has to date been synthesized with low to moderate molar activities (A m ’s). In certain cases, low A m can skew the estimation of specific binding. The high proportion of the non-radioactive component can reduce the apparent-specific binding by competitively binding to receptors. We developed a nucleophilic synthesis of [ 18 F]F-DPA resulting in high A m (990 ± 150 GBq/µmol) and performed in vivo comparison with low A m (9.0 ± 2.9 GBq/µmol) [ 18 F]F-DPA in the same APP/PS1-21 and wild-type mice (injected masses: 0.34 ± 0.13 µg/kg and 38 ± 15 µg/kg, respectively). The high level of microgliosis in the APP/PS1-21 mouse model enables good differentiation between diseased and healthy animals and serves better to distinguish the effect of differing A m on specific binding. The differing injected masses affect the washout profile and shape of the time–activity curves. Ratios of standardized uptake values obtained with high and low A m [ 18 F]F-DPA demonstrate that there is a 1.5-fold higher uptake of radioactivity in the brains of APP/PS1-21 animals when imaging is carried out with high A m [ 18 F]F-DPA. The differences between APP/PS1-21 and wild-type animals showed higher significance when high A m was used.
24